# Protocol 2 — Opioid-Free General Anesthesia (No Regional Blocks)

### Post-Mastectomy Breast Implant Revision

**Second-Line Pathway: Needle-Minimizing Approach** • Version 2.0 — December 2025

[![License: CC BY 4.0](https://img.shields.io/badge/License-CC%20BY%204.0-lightgrey.svg)](https://creativecommons.org/licenses/by/4.0/)

---

## Educational Use Disclaimer

**This protocol is an educational framework, not an institutional clinical guideline.**

- Developed for pre-medical educational purposes and medical school application portfolio
- NOT approved for clinical use without institutional review and attending physician oversight
- All clinical decisions require attending anesthesiologist judgment and patient-specific assessment
- Does not replace formal anesthesia training, credentialing, or institutional policies
- Author is pre-medical student; content reflects literature synthesis, not clinical expertise

**For clinical implementation:** This framework requires validation by board-certified anesthesiologists, institutional governance review, pharmacy approval, and integration with local policies. No protocol substitutes for individualized patient assessment and attending-level clinical judgment.

---

## Why Choose This Pathway?

**Key Advantages:**
- **Minimal needle sticks** (IV access only - no additional regional block needles)
- **True opioid-free anesthesia** maintained
- **Dramatically lower PONV** vs conventional opioid-based techniques (10-15% vs 25-40%)
- **Faster recovery** compared to opioid-based anesthesia
- **Patient-centered** approach for needle-phobic individuals

**Critical Success Factor:**
- **Robust surgeon local infiltration is ESSENTIAL** for this protocol
- Without adequate field block, pain control may be suboptimal
- Pre-surgical coordination with surgical team mandatory

**Best For:**
- Patients with needle phobia or extreme anxiety about injections
- Coagulopathy or therapeutic anticoagulation (blocks contraindicated)
- Local infection at planned block site
- High PONV risk but unable/unwilling to receive regional blocks
- Anatomic challenges making regional blocks technically difficult
- Time constraints precluding block placement

**Evidence Base:**
- ERAS Society guidelines support multimodal opioid-sparing techniques
- Multiple studies demonstrate OFA feasibility without regional blocks
- Surgeon infiltration critical component of multimodal analgesia
- Patient satisfaction high when expectations appropriately set

---

## Indications

**Patient Factors:**
- Patient refusal of regional blocks after informed discussion
- Needle phobia (anxiety disorder or strong preference)
- ASA I-III
- Apfel PONV score ≥2 (protocol beneficial for PONV reduction)
- Patient consent for opioid-free approach with understanding that pain control may be less robust than Protocol 1

**Clinical Contraindications to Regional Blocks:**
- Coagulopathy (INR >1.5, platelets <50,000)
- Therapeutic anticoagulation (per ASRA guidelines)
- Local infection at block site (cellulitis, abscess)
- Patient anatomy unfavorable (severe obesity, prior radiation, chest wall deformity)

**Surgical Factors:**
- Mild to moderate complexity revision
- Surgeon experienced with local infiltration techniques
- Surgeon committed to generous field block (20-40 mL local anesthetic)

---

## Contraindications

### Absolute Contraindications

| Contraindication | Rationale |
|------------------|-----------|
| **Patient refusal of opioid-free approach** | Autonomy; proceed to Protocol 3 |
| **True allergy to all multimodal agents** | No safe alternatives (rare scenario) |
| **Surgeon unwilling/unable to perform adequate infiltration** | Protocol 2 success depends on surgeon field block |

### Relative Contraindications (Assess Risk-Benefit)

| Consideration | Management Strategy |
|---------------|---------------------|
| **Severe COPD / CO₂ retention** | Dexmedetomidine respiratory depression rare but possible; monitor closely |
| **Uncontrolled tachyarrhythmia** | Ketamine sympathomimetic effect may worsen; consider lower dose or omit |
| **Anticipated extremely painful case** | Total capsulectomy, ADM revision, extensive dissection → **strongly consider Protocol 1** instead |
| **Baseline bradycardia (HR <50)** | Dexmedetomidine may worsen; use lower doses, monitor closely |
| **Significant hepatic dysfunction** | Reduce lidocaine dose or avoid; monitor for toxicity |
| **Renal impairment (severe)** | Caution with NSAIDs; adjust multimodal regimen |

**Important Clinical Decision Point:**
- If case complexity is high (extensive capsulectomy, ADM reconstruction, infection washout), **Protocol 1 strongly preferred** for superior analgesia
- Protocol 2 best suited for straightforward revisions (size exchange, mild contracture, implant malposition)

---

## Required Equipment and Preparation

### Monitoring Equipment

**Standard ASA Monitors:**
- Continuous ECG
- Pulse oximetry
- Non-invasive blood pressure (cycle q3-5 min)
- Capnography (continuous during intubation)
- Temperature monitoring
- Inspired/expired gas analysis

**Consider Adding:**
- Processed EEG (BIS, Entropy) if age >70, frailty, or desire for tight depth control
- Arterial line only if severe cardiac disease (rarely needed)

### Airway Equipment

**Standard:**
- Video laryngoscope (preferred)
- Endotracheal tubes (7.0-7.5 mm women, 7.5-8.0 mm men)
- OR supraglottic airway (LMA size 3-4 women, 4-5 men)

---

## Preoperative Preparation

### Multimodal Oral Premedication (Given 1-2 Hours Preoperatively)

| Medication | Dose | Indications | Contraindications |
|------------|------|-------------|-------------------|
| **Acetaminophen** | 1000 mg PO | **All patients** (unless hepatic dysfunction) | Severe hepatic impairment |
| **Celecoxib** | 200-400 mg PO | If no renal/GI contraindications | CKD stage 4-5, active PUD, ASA allergy |
| **Gabapentin** | **NOT routinely recommended** | Consider ONLY if neuropathic pain or severe anxiety AND age <65 | Age >75, cognitive impairment, OSA |

**Gabapentin Note:**
- Modern ERAS guidelines do NOT routinely recommend gabapentin due to sedation/delirium risk
- If used for severe needle phobia/anxiety: **300 mg maximum** (lower end of range)
- Avoid in elderly, cognitively impaired, or OSA patients
- **Not a substitute for appropriate anxiolysis** (midazolam preferred)

### Anxiolysis (Preoperative, Essential for Needle-Phobic Patients)

| Medication | Dose | Notes |
|------------|------|-------|
| **Midazolam** | 1-2 mg IV (can repeat to 4 mg total) | **Use liberally** in needle-phobic patients to reduce distress |
| | | Titrate to calm but arousable state |
| | | Document total dose for PACU awareness (delayed emergence possible) |

**For Severe Needle Phobia:**
- Consider starting IV with topical anesthetic (EMLA cream, lidocaine spray)
- Oral midazolam 0.5 mg/kg (max 20 mg) 30 min before IV if extreme anxiety
- Reassurance, calm environment, minimize visible needles/syringes

### Antibiotic Prophylaxis

| Weight | Medication | Timing |
|--------|------------|--------|
| **<120 kg** | Cefazolin 2 g IV | 30-60 min before incision |
| **≥120 kg** | Cefazolin 3 g IV | 30-60 min before incision |
| **β-lactam allergy** | Vancomycin 15 mg/kg IV (max 2 g) | 60-120 min before incision (slower infusion) |

**Re-dosing:**
- Cefazolin: q4h if case duration >4 hours
- Vancomycin: q12h (rarely needed for breast surgery duration)

### Antiemetic Prophylaxis (If Apfel ≥2)

**Preoperative (Choose 1-2 Based on Risk):**

| Apfel Score | Medications |
|-------------|-------------|
| **2** | Dexamethasone 4-8 mg IV |
| **3** | Dexamethasone 4-8 mg IV + Ondansetron 4 mg IV (before emergence) |
| **4** | Dexamethasone 8 mg IV + Scopolamine patch + Ondansetron 4 mg IV (before emergence) |

---

## Induction of General Anesthesia

### Pre-Induction Setup

**Patient Positioning:**
- Supine, arms tucked or on armboards
- Pressure point padding

**Monitoring:**
- Standard ASA monitors connected and functioning
- Baseline vital signs documented

**Pre-Oxygenation:**
- 100% O₂ for 3-5 minutes
- Target end-tidal O₂ >90%

### Induction Sequence (Opioid-Free, Enhanced Multimodal)

| Step | Agent | Dose | Purpose | Notes |
|------|-------|------|---------|-------|
| **1** | **Lidocaine** | 1.5 mg/kg IV (max 100 mg) | Blunt sympathetic response to laryngoscopy | Give 90 seconds before laryngoscopy if possible |
| **2** | **Ketamine** | 0.3-0.5 mg/kg IV | **Essential analgesic component** (no blocks) | **Higher dose than Protocol 1** to compensate for lack of regional |
| **3** | **Propofol** | 1.5-2 mg/kg IV | Induction of unconsciousness | **Reduce to 1-1.5 mg/kg if:** Age >70, frail, ASA III-IV |
| **4** | **Rocuronium** | 0.6-1 mg/kg IV | Neuromuscular blockade | Or succinylcholine 1-1.5 mg/kg if RSI indicated |

**Key Difference from Protocol 1:**
- **Ketamine dose is HIGHER** (0.3-0.5 mg/kg vs 0.2-0.3 mg/kg)
- Compensates for absence of regional block analgesia
- Critical for adequate pain control in this protocol

**Elderly/Frail Dosing Adjustments:**
- Propofol: 1-1.5 mg/kg (reduce 25-33%)
- Ketamine: 0.2-0.3 mg/kg (reduce to Protocol 1 dose range)
- Titrate slowly; allow time for circulation

**Contraindications to Ketamine:**
- Uncontrolled hypertension (SBP >180)
- Recent MI or unstable angina
- Active psychosis
- Severe coronary artery disease (relative)

**If Ketamine Contraindicated:**
- **Strongly reconsider Protocol 2** - analgesia will be suboptimal without both blocks AND ketamine
- Consider Protocol 3 (opioid-based) instead
- If proceeding: Maximize dex/lidocaine, ensure robust surgeon infiltration, anticipate higher PACU rescue needs

### Airway Management

**Endotracheal Intubation (Preferred):**
- Video laryngoscopy preferred for optimal view
- ETT size: 7.0-7.5 mm (women), 7.5-8.0 mm (men)
- Cuff pressure 20-30 cm H₂O

**Supraglottic Airway (LMA):**
- Acceptable alternative if short case and low aspiration risk
- Size 3-4 (women), 4-5 (men)

**Confirm Placement:**
- End-tidal CO₂ waveform
- Bilateral breath sounds
- Chest rise

---

## Maintenance of Anesthesia

### Hypnotic Agent (Choose ONE)

**Option A: Propofol TIVA (Preferred for PONV Prophylaxis)**

| Parameter | Dosing |
|-----------|--------|
| **Infusion Rate** | 75-150 mcg/kg/min (4.5-9 mg/kg/hr) |
| **Elderly/Frail** | 50-100 mcg/kg/min (3-6 mg/kg/hr) |
| **Target** | BIS 40-60 or clinical signs of adequate depth |

**Option B: Volatile Anesthetic (Sevoflurane/Desflurane)**

| Parameter | Dosing |
|-----------|--------|
| **MAC** | 0.7-1.0 MAC (age-adjusted) |
| **Sevoflurane** | 1.5-2.5% end-tidal |
| **Desflurane** | 4-6% end-tidal |

**Note:** Propofol TIVA preferred for PONV reduction in high-risk patients

### Multimodal Adjuncts (All Given - CRITICAL for Protocol 2 Success)

#### Dexmedetomidine Infusion (ESSENTIAL Component)

| Parameter | Dosing | Notes |
|-----------|--------|-------|
| **Loading Dose** | **AVOID** or 0.2-0.3 mcg/kg over 10 min | High risk of bradycardia/hypotension with bolus |
| **Maintenance** | **0.2-0.7 mcg/kg/hr** | **Higher range than Protocol 1** to compensate for no blocks |
| **Standard Dosing** | 0.4-0.7 mcg/kg/hr | Use upper end of range for analgesic benefit |
| **Elderly/Frail** | 0.2-0.4 mcg/kg/hr | Use lower end; increased sensitivity |
| **Taper** | Stop or reduce 10-15 min before end | Prevent prolonged sedation |

**Monitoring:**
- Continuous HR and BP
- If HR <50 or symptomatic bradycardia → reduce or stop infusion
- If MAP <65 persistently → reduce dose, consider phenylephrine

**Contraindications:**
- High-grade AV block without pacemaker
- Severe bradycardia (HR <45)
- Decompensated heart failure

**Key Difference from Protocol 1:**
- **Higher infusion rate** (up to 0.7 mcg/kg/hr vs 0.5 mcg/kg/hr max in Protocol 1)
- Provides additional analgesic and opioid-sparing effect
- Monitor carefully for hemodynamic effects

#### Lidocaine Infusion (ESSENTIAL Component)

| Parameter | Dosing | Notes |
|-----------|--------|-------|
| **Bolus** | 1.5 mg/kg IV at induction | Already given |
| **Maintenance** | **1.5-2 mg/kg/hr** | **Higher end of range** vs Protocol 1 |
| **Hepatic Dysfunction** | 0.5-1 mg/kg/hr or avoid | Reduced clearance |
| **Duration** | Continue through case, stop at closure | Or continue 1-2 hr postop per institutional protocol |

**Contraindications:**
- Severe heart block without pacemaker
- Severe hepatic dysfunction
- Allergy to amide local anesthetics

**Key Difference from Protocol 1:**
- **Use higher end of dosing range** (2 mg/kg/hr preferred vs 1-1.5 mg/kg/hr)
- Maximizes anti-inflammatory and analgesic benefits

#### Ketamine (ESSENTIAL - Multiple Dosing Options)

**Without regional blocks, ketamine is CRITICAL for adequate analgesia.**

**Option A: Induction Bolus + Intermittent Microboluses (Recommended)**
- **Induction:** 0.3-0.5 mg/kg (already given)
- **Intraoperative microboluses:** 10-20 mg IV q30-45 min or as needed for surgical stimulus
- **Total cumulative dose:** Typically 0.5-0.8 mg/kg over 1-2 hour case

**Option B: Continuous Infusion (Alternative)**
- **Induction bolus:** 0.3-0.5 mg/kg
- **Maintenance infusion:** 0.1-0.25 mg/kg/hr
- **Higher range than Protocol 1** (0.25 mg/kg/hr vs 0.2 mg/kg/hr max)

**Option C: Hybrid (Bolus + Low-Dose Infusion)**
- **Induction:** 0.3-0.5 mg/kg
- **Maintenance:** 0.1-0.15 mg/kg/hr baseline
- **Supplemental boluses:** 10-20 mg for intense surgical stimulation

**Not a Substitute for Adequate Depth:**
- Ensure propofol/volatile agent adequate first
- Ketamine is analgesic adjunct, not primary hypnotic

**Elderly Dosing:**
- Reduce to Protocol 1 dosing (0.2-0.3 mg/kg induction, 0.1-0.2 mg/kg/hr infusion)

### Ventilation Strategy

**Lung-Protective Ventilation:**

| Parameter | Target |
|-----------|--------|
| **Tidal Volume** | 6-8 mL/kg ideal body weight |
| **Respiratory Rate** | 10-14 breaths/min (adjust for EtCO₂) |
| **PEEP** | 5-8 cm H₂O |
| **FiO₂** | 0.4-0.5 (target SpO₂ >94%) |
| **EtCO₂** | 35-40 mmHg |

**Avoid:**
- Excessive tidal volumes (>10 mL/kg)
- Hyperventilation (EtCO₂ <30)
- FiO₂ >0.8 unless hypoxemic (ERAS guideline)

---

## Intraoperative Management

### Hemodynamic Goals

| Parameter | Target Range | Management |
|-----------|--------------|------------|
| **MAP** | 65-90 mmHg (or ±20% of baseline) | Phenylephrine 50-100 mcg IV for hypotension |
| **Heart Rate** | 50-90 bpm | Reduce dex if <50; glycopyrrolate 0.2 mg if symptomatic |
| **SpO₂** | ≥94% | Increase FiO₂, check ventilator settings |

**Hypotension Management:**
- **First-line:** Phenylephrine 50-100 mcg IV bolus
- **If bradycardic:** Ephedrine 5-10 mg IV
- **Persistent:** Reduce dexmedetomidine (likely cause), ensure adequate fluid status

**Bradycardia Management:**
- **More common in Protocol 2** (higher dex dosing)
- **Asymptomatic, HR >45:** Observe, reduce dexmedetomidine to 0.3-0.4 mcg/kg/hr
- **Symptomatic or HR <45:** Glycopyrrolate 0.2-0.4 mg IV
- **Severe (<40):** Stop dexmedetomidine, atropine 0.5-1 mg IV

### Fluid Management

**Goal-Directed, Restrictive Strategy (ERAS Principles):**

| Fluid Type | Rate | Total |
|------------|------|-------|
| **Crystalloid** | 2-4 mL/kg/hr maintenance | Goal: <1500 mL total for 1-2 hr case |
| **Replacement** | 1:1 for estimated blood loss | Typically minimal in breast revision |

**Avoid Excessive Fluids:**
- Associated with edema, delayed recovery, increased PONV
- Use vasopressors to maintain MAP rather than fluid boluses

### Temperature Management

**Maintain Normothermia:**
- Forced air warming blanket
- Warmed IV fluids if large volume
- Target core temperature >36°C

### Surgeon Local Infiltration (CRITICAL for Protocol 2)

**Pre-Surgical Coordination MANDATORY:**

**Discuss with Surgeon:**
- Protocol 2 relies heavily on field block for analgesia
- Request generous local infiltration (20-40 mL total)
- Coordinate local anesthetic type and dose to avoid toxicity

### Recommended Surgeon Infiltration Technique

**Local Anesthetic Options:**

| Agent | Concentration | Volume | Total Dose | Duration |
|-------|---------------|--------|------------|----------|
| **Ropivacaine** | 0.2-0.375% | 20-40 mL | 40-150 mg | 4-8 hours |
| **Bupivacaine** | 0.25% | 20-30 mL | 50-75 mg | 4-8 hours |
| **Lidocaine** | 0.5-1% | 20-30 mL | 100-300 mg | 1-2 hours |

**Infiltration Sites:**
1. **Subcutaneous tissues** along planned incision
2. **Pectoralis major muscle** at dissection planes
3. **Pocket** (anterior and posterior surfaces)
4. **Around drains** if placed
5. **Final infiltration** before skin closure

**Timing:**
- **Before incision:** Skin and subcutaneous
- **During pocket dissection:** Deeper tissues
- **Before closure:** Final liberal infiltration

**Safety Considerations:**
- **Total local anesthetic dose** must account for BOTH lidocaine infusion AND surgeon infiltration
- **Anesthesiologist must document** lidocaine infusion total dose
- **Surgeon must document** infiltration agent, concentration, volume
- **Combined dose** should not exceed safe maximums:
  - Lidocaine: 4.5 mg/kg with epinephrine (7 mg/kg with epi)
  - Ropivacaine: 3 mg/kg with epinephrine
  - Bupivacaine: 2.5 mg/kg with epinephrine

**Example Calculation (70 kg patient):**
- **Lidocaine infusion:** 2 mg/kg/hr × 1.5 hr = 210 mg
- **Surgeon infiltration:** Bupivacaine 0.25%, 30 mL = 75 mg
- **Total:** Different agents, both within safe limits ✓

**If using lidocaine for both infusion AND infiltration:**
- **MUST reduce one or the other**
- Example: Lidocaine infusion 150 mg + surgeon infiltration 200 mg = 350 mg total (5 mg/kg for 70 kg) - SAFE with epinephrine
- Maximum: 7 mg/kg with epi = 490 mg for 70 kg

**Communication Protocol:**
- Before incision: "Surgeon, we're using Protocol 2 - please plan generous field block"
- During case: "I've given X mg lidocaine IV infusion"
- Surgeon: "I'm using [agent] [concentration] [estimated volume]"
- Anesthesiologist: Calculate total, confirm safe or adjust

---

## Emergence and Extubation

### Emergence Protocol (~10-15 Minutes Before Anticipated End)

**Taper Infusions:**

| Agent | Taper Strategy |
|-------|----------------|
| **Dexmedetomidine** | Stop or reduce to 0.1-0.2 mcg/kg/hr 10-15 min before end |
| **Lidocaine** | Stop at skin closure or continue 1-2 hr postop per protocol |
| **Ketamine** | Stop 5-10 min before end if infusion used |
| **Propofol** | Taper for awakening at skin closure; target BIS 70-80 for emergence |

**Antiemetic Prophylaxis:**
- **Ondansetron 4 mg IV** before emergence (if not already given and Apfel ≥2)
- Consider **additional agent** if Apfel 4 and high-risk patient

**Neuromuscular Blockade Reversal:**
- **Sugammadex 2-4 mg/kg IV** (preferred for reliable reversal)
  - 2 mg/kg if TOF 2-4 twitches
  - 4 mg/kg if TOF 0-1 twitch or deep block
- **OR Neostigmine 0.04-0.07 mg/kg + Glycopyrrolate 0.01 mg/kg**
  - Only if TOF ≥2 twitches
  - Max neostigmine 5 mg

### Extubation Criteria

**Standard Extubation (For Protocol 2 - OFIA):**

| Criterion | Assessment |
|-----------|------------|
| **Awake** | Following commands, eyes open |
| **Adequate Ventilation** | RR 10-20, strong respiratory effort, VT >5 mL/kg |
| **Oxygenation** | SpO₂ >92% on minimal supplemental O₂ |
| **Hemodynamics** | Stable HR and BP |
| **Neuromuscular Function** | TOF ratio >0.9, sustained head lift >5 sec, strong hand grip |

**Do NOT Extubate If:**
- Somnolent (RASS ≤-2)
- Inadequate ventilation or oxygenation
- Hemodynamically unstable
- Residual neuromuscular blockade (TOF <0.9)

**Post-Extubation:**
- 100% O₂ by face mask initially
- Encourage deep breathing
- Position head-up 30-45°

---

## PACU Management

### Expected Clinical Course

**Typical Protocol 2 PACU Course:**
- **Pain:** NRS 3-6/10 (variable, depends on surgeon infiltration quality)
- **Sedation:** Minimal to mild (RASS 0 to -1)
- **PONV:** Low-moderate risk (10-15%)
- **Hemodynamics:** Generally stable
- **Duration:** 90-120 minutes to discharge readiness

**Comparison to Protocol 1:**
- **Higher pain scores expected** (no regional blocks)
- **More rescue analgesia needed** (20-40% vs <20% in Protocol 1)
- **Longer PACU stay** due to pain management titration

### Monitoring Requirements

| Parameter | Frequency | Duration |
|-----------|-----------|----------|
| **Vital Signs** | Q15 min initially → Q30 min when stable | Until discharge |
| **Pulse Oximetry** | Continuous until stable and awake | ~90 min |
| **RASS Score** | Q15-30 min | Until discharge |
| **Pain Score (NRS)** | Q15-30 min | Until discharge |

**Enhanced Monitoring (vs Protocol 1):**
- More frequent pain assessments due to anticipated higher rescue needs
- Longer continuous SpO₂ monitoring (90 min vs 60 min)

### Pain Management (Multimodal Foundation)

**Scheduled Non-Opioid Analgesics:**

| Medication | Dose | Frequency | Notes |
|------------|------|-----------|-------|
| **Acetaminophen** | 1000 mg PO | Q6h scheduled | If not already given preop |
| **Ketorolac** | 15 mg IV | Q6h × 48 hours | **Preferred NSAID** for first-line |
| **OR Celecoxib** | 200 mg PO | Q12h | Alternative if ketorolac contraindicated |

**Contraindications to NSAIDs:**
- CKD stage 4-5 (eGFR <30)
- Active peptic ulcer disease
- ASA/NSAID allergy
- Severe hepatic dysfunction

### Rescue Analgesia Protocol (Protocol 2-Specific)

**Expected:** 20-40% of patients will require rescue analgesia (vs <20% in Protocol 1)

**If Pain NRS ≥4 Despite Scheduled Multimodal:**

**Step 1: Assess Surgeon Infiltration Quality**
- Ask patient about numbness at surgical site
- If clearly no effect from infiltration → anticipate higher rescue needs

**Step 2: Multimodal Rescue Options**

| Pain Level | First-Line Rescue | Second-Line | Third-Line |
|------------|-------------------|-------------|------------|
| **NRS 4-6** | Ketamine 10-20 mg IV (if institutional protocol permits) | Hydromorphone 0.2-0.4 mg IV q15-20 min | Additional NSAID if not maxed |
| **NRS ≥7** | Ketamine 20-30 mg IV + Hydromorphone 0.2-0.4 mg IV | Hydromorphone 0.4-0.8 mg IV q15-20 min | Consider ketamine infusion 0.1-0.2 mg/kg/hr |

**Ketamine-First Strategy (Preferred for Protocol 2):**
- Maintains opioid-free approach as long as feasible
- 10-20 mg IV boluses can be repeated q15-20 min
- Total PACU ketamine often 30-60 mg
- If institutional protocol allows, ketamine infusion 0.1-0.2 mg/kg/hr for 1-2 hours

**Opioid Rescue (When Ketamine Inadequate or Contraindicated):**

| Patient Phenotype | Hydromorphone Dose | Interval | Monitoring |
|-------------------|-------------------|----------|------------|
| **Opioid-naïve, elderly, frail** | 0.2 mg IV | Q20-30 min | Continuous SpO₂ |
| **Standard adult** | 0.2-0.4 mg IV | Q15-20 min | Continuous SpO₂ until stable |
| **Chronic opioid use** | 0.4-0.8 mg IV | Q15-20 min | Higher tolerance expected |
| **OSA** | 0.2 mg IV | Q30 min | Enhanced monitoring, lower threshold for capnography |

**If High Rescue Needs (>4 mg hydromorphone equivalent in PACU):**
- Reassess multimodal regimen adequacy
- Consider ketamine infusion if not already started
- Attending anesthesiologist evaluation
- Possible late surgeon infiltration (rarely feasible)
- Set expectations: Protocol 2 has inherent analgesic limitations vs Protocol 1

**Converting to Home Analgesia:**
- If high PACU rescue needs, likely will need short-term opioid prescription
- Counsel on opioid risks, storage, disposal
- Typical: Oxycodone 5 mg PO q4-6h PRN × 15-20 tablets

### PONV Management

**Prevention (Already Done):**
- TIVA with propofol (if used)
- Dexamethasone preoperatively
- Ondansetron before emergence

**Treatment If PONV Occurs (Despite Prophylaxis):**

| Episode | Treatment | Dose |
|---------|-----------|------|
| **First** | Ondansetron | 4 mg IV (if not already given) |
| **Second** | Metoclopramide | 10 mg IV |
| **Third** | Promethazine | 6.25-12.5 mg IV (sedating) |
| **Refractory** | Haloperidol | 0.5-1 mg IV (off-label, effective) |

### Discharge Readiness Criteria

**Modified Aldrete Score ≥9 (PACU Discharge):**

| Criterion | Score |
|-----------|-------|
| **Activity** | Moves 4 extremities = 2; Moves 2 extremities = 1; No movement = 0 |
| **Respiration** | Deep breathing, coughing = 2; Dyspnea, shallow = 1; Apnea = 0 |
| **Circulation** | BP ±20 mmHg baseline = 2; BP ±20-50 mmHg = 1; BP ±>50 mmHg = 0 |
| **Consciousness** | Fully awake = 2; Arousable = 1; Not responding = 0 |
| **O₂ Saturation** | SpO₂ >92% room air = 2; SpO₂ >90% with
